Results 271 to 280 of about 53,090 (292)

Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy

Expert Opinion on Biological Therapy, 2020
Cameron J Turtle
exaly  

B Lymphocyte Antigen CD19

2016
openaire   +1 more source

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

Blood, 2012
James N Kochenderfer, Mark E Dudley, Steven A Feldman   +2 more
exaly  

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

Blood, 2010
James N Kochenderfer, Zhiya Yu, Nicholas P Restifo   +2 more
exaly  

Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice

Molecular Therapy, 2018
Christopher A Pennell, Angela Panoskaltsis-Mortari, Michael Loschi   +2 more
exaly  

Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes.

Journal of Experimental Medicine, 1993
R H Carter, L B Klickstein, J M Ahearn
exaly  

A New Frontier: CD19 Chimeric Antigen Receptor T-Cell Therapy

Pediatric Annals
Lolita, Alcocer Alkureishi, Joseph R, Hageman   +1 more
openaire   +2 more sources

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Annals of Oncology, 2018
W Jurczak, Pier Luigi Zinzani, Gianluca Gaidano   +2 more
exaly  

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Molecular Therapy, 2017
Frederick L Locke, Sattva S Neelapu, Nancy L Bartlett   +2 more
exaly  

CD19 regulates B lymphocyte responses to transmembrane signals

Seminars in Immunology, 1998
Manabu Fujimoto, Jonathan C Poe, Thomas F Tedder   +2 more
exaly